Traumatic brain injury (TBI) is the primary cause of death and disability in younger individuals \[[@CIT0001]\]. To date, the mechanism behind the cognitive dysfunction following TBI remains unclear. Neurotransmitters (NT) represent a particularly important system in physiological events relevant to cognition affected by TBI \[[@CIT0002]\]. Preclinical evaluations of both agonists and antagonists affecting acetylcholine (Ach) and the dopamine (DA) system have shown marked benefits for cognitive recovery.

Hence, the aim of this article is to outline clinical studies that have shown potential efficacy of Ach- and DA-oriented medications in the treatment of TBI.

PubMed was used to search for articles published since 1998 that reported any association between cognitive dysfunction following TBI. Before 1998, no clinical studies regarding the neurotransmitter-targeted therapies in TBI had been reported. After reviewing the abstracts, 14 articles were submitted to the final evidence review.

Acetylcholinesterase (AChE) inhibitors are most beneficial for the treatment of posttraumatic cognitive impairments \[[@CIT0003]\]. Principally, rivastigmine improved the cognitive function in TBI patients \[[@CIT0004]\]. However, the results from randomized controlled trials have remained modest \[[@CIT0005]\]. Zhang *et al*. \[[@CIT0006]\] performed a 24-week, randomized, placebo-controlled, double-blind crossover trial to demonstrate sustained improvements in immediate auditory and visual memory, attention, working memory and information processing speed. An open-label study conducted by Tenovuo \[[@CIT0007]\] also found a subjective and longer (average 24 months) improvement following donepezil (summarized in [Table I](#T0001){ref-type="table"}).

###### 

Acetylcholinesterase inhibitors for cognitive rehabilitation after TBI

  Study              Design                                   Participants                             Interventions                                                              Primary outcomes                                                               Notes
  ------------------ ---------------------------------------- ---------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------ -------------------------------------------------
  Silver *et al*.    26-week double-blind open-label          134 adults with TBI                      12 mg daily of rivastigmine                                                Verbal learning test visual information processing                             An extension study
  Tenuvuo *et al*.   8-week                                   69 patients with TBI                     12 mg daily rivastigmine                                                   Computerized neuropsychological testing and standardized clinical interviews   A weak trend favoring rivastigmine was observed
  Zhang *et al*.     RCT crossover, double blind              18 participants with mild-severe TBI     5--10 mg/day of donepezil                                                  [^\*^](#TF0001){ref-type="table-fn"} AII, VII PASAT                            
  Tenovuo *et al*.   Retrospective pseudo-randomized cohort   111 patients with mild to moderate TBI   5 mg/day of donepezil 4 mg/day of galantamine 1.5 mg/day of rivastigmine   Self-assessment rated from no response to excellent response                   No differences were found among the three drugs

AII indicates Auditory Immediate Index, VII -- Visual Immediate Index, PASAT -- Paced Auditory Serial Addition Test.

Dopamine represents a unique role in the NT system within the central nervous system (CNS) due to its influences on a number of physiologic functions including working memory, behavioral flexibility, and decision making \[[@CIT0008]\].

In 2006, the Neurotrauma Foundation (NTF) recommended three drugs with DAergic effects to be used in TBI patients to enhance cognitive recovery and rehabilitation \[[@CIT0009]\]. The identified drugs were methylphenidate (MPD), amantadine hydrochloride (AMH), and bromocriptine \[[@CIT0009]\].

Multiple studies have demonstrated the effectiveness of MPD used in TBI patients with cognitive dysfunction especially in information processing speed \[[@CIT0010]\], attention \[[@CIT0011], [@CIT0012]\], alertness \[[@CIT0013]\], and working memory \[[@CIT0014]\] after brain trauma. However, there is no longer than six months follow-up in the clinical trials regarding MPD in patients with TBI.

Amantadine hydrochloride has also been found to be effective at treating cognitive dysfunction post-TBI in both clinical trials and case reports. Kraus *et al*. \[[@CIT0015]\] showed that AMH treatment improved prefrontal executive function in TBI patients correlated with an increase in left prefrontal cortex glucose metabolism. Patrick *et al*. \[[@CIT0016]\] reported that AMH accelerated recovery of attention deficit in children with a lower response following brain injury.

Bromocriptine is a specific D2 receptor agonist, and a past case report \[[@CIT0017]\] showed improvements in motor function and executive function after administering bromocriptine in a severe TBI patient associated with Parkinson\'s syndrome. In contrast, McDowell *et al*. did not find that bromocriptine appeared to improve attentional difficulties in moderate to severe TBI patients. However, this study employed a relatively high dose of bromocriptine at 10 mg/day for a more prolonged treatment period than previously studied in TBI \[[@CIT0018]\]. In addition, a 6-week placebo-controlled pilot study showed that bromocriptine in TBI patients also did not enhance attentional skills \[[@CIT0019]\] (summarized in [Table II](#T0002){ref-type="table"}).

###### 

Dopamine drugs for cognitive rehabilitation after TBI

  Study                  Design                                                            Participants                                                     Interventions                     Primary outcomes                                                                                                           Notes
  ---------------------- ----------------------------------------------------------------- ---------------------------------------------------------------- --------------------------------- -------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------
  Whyte *et al*.         6-week double-blind placebo-controlled repeated crossover study   34 adults with moderate to severe TBI and attention complaints   0.3 mg/kg dose MPD, twice a day   Processing speed Work attentiveness Caregiver rating of attention Reaction time                                            
  Pavlovskaya *et al*.   4-week                                                            6 patients with severe TBI                                       5--10 mg/day of MPD               Author-modified Attention based performance                                                                                No objective assessment
  Willmott *et al*.      RCT, crossover, double blind                                      40 participants with moderate-severe TBI                         0.3 mg/kg twice daily of MPD      Processing speed Selective attention task Dissimilar compatible                                                            
  Lee *et al*.           4 week double-blind parallel-group trial                          30 patients with mild to moderate TBI                            5--20 mg/day of MPD               MMSE                                                                                                                       
  Kim *et al*.           Double-blind placebo-controlled study                             18 subjects with TBI                                             20 mg/day of MPD                  Working memory and visuospatial attention tasks                                                                            
  Kraus *et al*.         An open-label design                                              Twenty-two subjects with TBI                                     400 mg/day of AMH                 Neuropsychological test Executive function                                                                                 
  Patrick *et al*.       A retrospective review                                            10 children with severe TBI and a low response state             100--400 mg/day of AMH            Arousal/attention and auditory response Expressive communication visual response Tactile response and olfactory response   
  Ben *et al*.           Case report                                                       An old patient with severe TBI associated with PD                AMH (unknown dose)                Author modified tests Motor function and cognitive function                                                                
  McDowell *et al*.      RCT cross over                                                    24 patients with severe TBI                                      1 dose of bromocriptine           Executive function                                                                                                         No effect on the working memory Related to prefrontal function
  McAllister *et al*.    Unblinded controlled study                                        26 individuals with mild TBI                                     1.25 mg bromocriptine             A neuropsychological test battery                                                                                          

This brief review has sought to summarize the evidence that supports an NT-oriented hypothesis of cognitive dysfunction after TBI and provide a context for the use of Ach and DA targeted therapies during patient rehabilitation.

In conclusion, it seems that applications of AChE inhibitors and DA agonists are beneficial in TBI patients with cognitive dysfunction.
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